During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...

Carnival Cruise Line had to deliver quite a bit of bad news ... that cruise ships undergo every few years — resulted in multiple cancelled cruises. The drydock for Carnival Magic, which sails ...

William Blair analyst Matt Phipps has estimated that there are around 3,000 multiple myeloma patients in the US who get fifth-line treatment per year. That rises to 6,000 for fourth-line therapy ...

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Among the most significant areas of concern are two on the offensive line, multiple areas of the secondary, and the running back position. Draft rumors and news continue to build up as round one ...

He’s already won the crowd. As the 27-year-old NBA nomad — at least, before he arrived in Cleveland two years ago — stepped to the free-throw line multiple times in the fourth quarter ...